Dhaka 16 September, 2026

Covid-19 testing still vital even as vaccines roll out: WHO Chief

Rtv news

Publish : 28 Nov 2020, 11:29 AM
Tedros Adhanom Gheybreyesus

Tedros Adhanom Gheybreyesus, the head of the World Health Organization (WHO) on Friday said testing will still be a critical tool against COVID-19, even as vaccines are deployed against the disease.

The WHO chief also emphasized on how testing has been common among countries which have worked to control the virus, during his regular briefing on the crisis, reports UN news.

“As vaccines are rolled out, testing will continue to play a vital role”, he said.

“Initially, health workers, older people and other at-risk groups will be prioritised for vaccination. That will still leave the virus with a lot of room to move, and testing will remain a vital tool for controlling the pandemic.”

However, Tedros stressed that though vital, testing is only part of the strategy against COVID-19.

“Testing is the spotlight that shows where the virus is. Investments in testing must be matched by investments in isolation facilities, clinical care, protecting health workers, contact tracing, cluster investigation and supported quarantine”, he stated.

More evaluation needed

Meanwhile, WHO said more information is needed concerning the vaccine developed by the pharmaceutical company AstraZeneca and Oxford University.

The partners announced this week that clinical trials showed a regimen consisting of one half-dose of the vaccine, followed by a full dose a month later, was more effective than two full doses.

Dr. Katherine O’Brien, Director of Immunization, Vaccines and Biologicals at WHO, underlined the need for further evaluation as the data were reported in a press release.

“I think what we can emphasize, though, is that from what we understand about the press release, there is certainly something interesting that has been observed. But there are many reasons that could underlie the differences that were observed,” she said.

WHO’s Chief Scientist, Dr. Soumya Swaminatha, pointed out that less than 3,000 people were given the lower-dose regimen, according to the press release, all of whom were 55 years old or younger.

She added that the other group consisted of more than 8,000 people of varying ages, thus making it very hard to compare the two, while overall, their numbers were too small to come to any definitive conclusions.

“It would be speculation at this point,” Dr. Swaminathan told reporters.

She said AstraZeneca has informed WHO that it intends to run a full trial of the lower-dose regimen.

Lessons from Ebola

Global experience with storage and distribution of the Ebola vaccine could inform delivery of any potential inoculation against COVID-19 once developed, according to WHO.

“There is demonstrated experience of delivering ultra-cold chain vaccines, even in some of the most difficult and remote areas,” said Dr. O’Brien. “But that has also taken enormous resources to do that.”

The WHO official was responding to a journalist’s question concerning the experimental vaccine developed by pharmaceutical companies Pfizer and BioNTech, which was recently submitted to authorities in the United States for emergency approval.

The vaccine, which has shown a more than 90 per cent efficacy rate, requires very cold storage of -70 degrees Celsius or below, prompting concerns about potential distribution in African countries.

No one vaccine is enough

“We do have experience in a number of countries, specifically in Africa, being able to deploy a vaccine with that ultra-cold chain requirement”, said Dr. O’Brien, referring to the Merck Ebola vaccine used in outbreaks in the Democratic Republic of the Congo.

“So, as we anticipate the use of the Pfizer vaccine, the intention is certainly to be able to use it along with other vaccines because no one vaccine is going to have adequate supply, nor will any one vaccine necessarily have suitable operational characteristics to meet all of the needs.”

Dr. O’Brien added that Pfizer has developed a special “shipper” which can maintain the vaccine’s temperature for up to 10 to 15 days.

Furthermore, the vaccine can be stored at refrigerated temperatures for five days, she continued, while portable freezers that do not run on electricity, and even dry ice, also can be used.

Innovate for delivery

As ultra-cold chain logistics are not in place everywhere, including in high-income nations, Dr. O’Brien suggested that countries will have to “innovate” around systems for delivering COVID-19 vaccines that have this requirement.

One approach could be to use them for immunizing certain segments of the population.

She cited health professionals as an example, because they work in facilities where immunization would take place and where it would be easier to install the ultra-cold chain freezers.

Move your body

Although the pandemic has imposed many restrictions on our lives, there is no excuse to sit on the couch, WHO affirmed on Friday, announcing new guidelines on physical activity and sedentary behaviour, published this week.

Exercise is essential for physical and mental health throughout life, the agency said, but one in four adults, and four in five adolescents, do not move enough.

The guidelines recommend between 150 and 300 minutes of moderate to vigorous activity per week for adults, and an average of 60 minutes per day for children and adolescents.

Source: UNB

AH

Follow google news channel to get RTV news Google News
UK approves AstraZeneca-Oxford virus vaccine as pandemic surges
Britain on Wednesday became the first nation to approve the coronavirus vaccine developed by AstraZeneca and the University of Oxford, as Germany logged its highest daily death toll with the pandemic surging worldwide. Fears have also grown following the detection in Britain of a new strain of the virus experts fear is more transmissible, and the variant has been found in a number of other countries, including the United States and India. The pandemic prompted unprecedented global efforts to develop vaccines in record time, and following Pfizer-BioNTech and Moderna, the AstraZeneca-Oxford candidate became the third to win approval in the Western world. “It is truly fantastic news,” tweeted British Prime Minister Boris Johnson. “We will now move to vaccinate as many people as quickly as possible.” Unlike the Pfizer-BioNTech and Moderna vaccines, the one from AstraZeneca and Oxford does not need to be stored at very low temperatures. It can be kept, transported and handled at normal refrigerated conditions, making it easier and cheaper to administer and a much smaller logistical challenge, especially for less wealthy nations. Russia and China also claim to have developed Covid-19 vaccines, and have already started administering them. Chinese pharma giant Sinopharm on Tuesday said that Phase 3 trials of its candidate had shown 79 percent effectiveness, close to the more than 90 percent achieved by Pfizer-BioNTech and Moderna. The firm has applied to China’s drug regulator for approval. But Beijing has struggled to gain international trust for its vaccines, hindered by a lack of data transparency as well as criticism over its handling of the initial outbreak of the virus in the central Chinese city of Wuhan and its attempts to silence whistleblowers. The number of infections in that city may have been 10 times higher than official figures suggest, according to a study by China’s Centre for Disease Control. – New variant worries – Even as vaccinations ramp up in Europe and North America, global infections have surged close to 82 million, with nearly 1.8 million deaths. Germany, which had handled the first coronavirus wave relatively well, has been hit hard by the second. It logged more than 1,000 daily deaths for the first time, authorities said Wednesday. Fears have also grown with the recent detection in Britain of a virus variant experts believe could be more transmissible. The variant has been detected in a number of other countries, after pushing Britain to a new daily record of infections. Indian authorities were trying Wednesday to track down tens of thousands of people who arrived from Britain in recent weeks as cases of the new variant more than doubled in 24 hours. The variant was detected for the first time in the United States and Latin America on Tuesday. The EU health agency has warned the strain carried a high risk for more hospitalisations and deaths — not because the infections are more severe but because it spreads more easily. – ‘Greatest operational challenge’ – In the United States — the worst-hit nation in the world — President-elect Joe Biden called mass vaccination “the greatest operational challenge we’ve ever faced as a nation”. The Trump administration had predicted that 20 million Americans would be vaccinated by the end of December. But with days left, just over two million have received the first shot of the vaccine, according to the Centers for Disease Control and Prevention. Biden, who takes over from Donald Trump on January 20, renewed his promise to administer 100 million vaccine doses in his first 100 days in office, and confirmed he would invoke a Korean War-era law to force private industry to step up production. “The Trump administration’s plan to distribute vaccines is falling far behind,” Biden said, promising: “I’m going to move Heaven and Earth to get us going in the right direction.” But he warned: “The next few weeks and months are going to be very tough –– a very tough period for our nation, maybe the toughest during this entire pandemic.” Source: AFP AH
UK approves AstraZeneca-Oxford virus vaccine as pandemic surges
LatAm countries begin mass vaccinations as Europe fears new strain
Three Latin American countries launched mass immunization programs on Thursday as fears grew in Europe over a variant coronavirus strain that is believed to be far more contagious than the original version. Frontline medical staffs in Mexico and Chile were among the first to receive their vaccines while Costa Rica began its own immunization program, with President Carlos Alvarado hailing what “may be the beginning of the end of this pandemic.” But global optimism was tempered as China and Brazil joined more than 50 governments restricting flights from Britain or air traffic in both directions, after the highly infectious new coronavirus strain first appeared there. Thousands of trucks remained stranded at a major British port as France sent 10,000 kits to test drivers before allowing them to cross the Channel. Despite the new strain that British Prime Minister Boris Johnson said was “up to 70 percent more transmissible” than the original coronavirus, Britain said rail and sea links with France would remain open over Christmas. Mexico televised the start of its mass immunization program after it received its first 3,000 doses of the Pfizer/BioNTech vaccine from Belgium. “It’s the best gift I could receive in 2020,” 59-year-old Mexican nurse Maria Irene Ramirez said as she received the injection at a hospital in the capital. Mexico has registered more than 120,000 Covid-19 deaths — the world’s fourth highest toll after the United States, Brazil and India. In Chile, 46-year-old nursing assistant Zulema Riquelme was the first person shown receiving the jab in the presence of President Sebastian Pinera. “I’m very excited and nervous,” she said, hours after the first 10,000 doses of the Pfizer-BioNTech vaccine arrived by plane. Elizabeth Castillo, a wheelchair-bound, 91-year-old nursing home resident, was the first person in Costa Rica to be vaccinated. “I am very grateful to God, because I have asked so much of him. My life is very important to me, so take advantage of every moment,” she said. Argentina, meanwhile, received the first 300,000 doses of Russia’s controversial Sputnik V vaccine on Thursday on a special flight from Moscow. The country is the first in Latin America to approve the Russian vaccine. Argentina’s President Alberto Fernandez has vowed to receive the first Sputnik V shot to prove it is reliable after criticism that it was registered before the start of large-scale clinical trials. – Covid deaths to increase in 2021 – Some of the thousands of lorry drivers stuck near the British port of Dover said they feared there was little chance of making it back into mainland Europe in time for the holidays. “Home for Christmas? Forget it,” said Laurent Beghin, a French trucker who has been stranded in England since Sunday. British Transport Minister Grant Shapps gave some hope in a Twitter post revealing that the rail and sea border with France would “remain open.” Passengers with negative virus tests on Wednesday boarded the first Eurostar trains from London to France since border closures were introduced on Sunday. The new strain of the virus that surfaced in Britain and has been detected in small numbers elsewhere, appeared for the first time in Germany after a woman flew in from London. Although it appears to spread more easily, experts say there is no evidence it is more lethal or resistant to vaccines. But the new variant, which is on average 56 percent more contagious, is likely to boost hospitalizations and deaths from Covid-19 next year, according to a study by the Centre for Mathematical Modelling of Infectious Diseases at the London School of Hygiene and Tropical Medicine. New restrictions came into force on Thursday in Italy, one of the worst-hit countries with more than 70,000 reported coronavirus deaths — half of them in the past three months. Austria allowed its more than 400 ski stations to open on Thursday, just two days before entering a third nationwide lockdown that will force shops and much of the service industry to close until mid-January. Israel said it would announce a third national lockdown from 5:00 pm (1500 GMT) on Sunday for two weeks. – Vatican mass brought forward – Fears over the new strain and surging coronavirus infections in general across Europe have severely dampened the mood over the holiday season. Russia on Thursday registered a record 29,935 new infections, bringing the country’s caseload to more than 2.96 million — the fourth-highest in the world. It also posted 635 deaths over the last 24 hours, another record, increasing the toll to over 53,000. Germany has been forced to cancel its famous Christmas markets and Pope Francis plans to bring the Vatican’s Christmas midnight mass forward by two hours to meet Italy’s curfew rules. The European Union is preparing to kick off vaccinations across the bloc on Sunday, hoping to turn the corner in the fight against the virus, which has infected more than 78 million people worldwide with more than 1.7 million deaths. French President Emmanuel Macron’s office meanwhile said he was free of Covid-19 symptoms, a week after testing positive. Despite a new cluster of cases, Australia’s biggest city Sydney still plans to celebrate the start of 2021 with its famous Harbour Bridge fireworks — but people are being encouraged to watch it on TV at home. In Bethlehem — which Christians believe is the birthplace of Jesus Christ— Christmas mass will be held without worshippers and broadcast online. Egypt has called off all New Year’s celebrations in order to stem a rise in cases. Source: AFP/BSS AH
LatAm countries begin mass vaccinations as Europe fears new strain
Covid-19 vaccine not a ‘silver bullet’: WHO
Vaccine is not a "silver bullet" that will end the nearly year-long pandemic which have already killed over 1.6 million, said  the World Health Organization (WHO) regional office for the Western Pacific on Thursday and it called for greater vigilance amid the roll-out of Covid-19 vaccine. "Whoever you are, wherever you live, as long as the virus is circulating somewhere, we all remain at risk, and we must keep preparing for the worst-case scenario," WHO Regional Director for the Western Pacific Takeshi Kasai said in a virtual media briefing, reports Xinhua.   Kasai appealed to the younger and socially active people aged under 40 to "do everything you can to avoid infection for yourself and everybody around you" despite the anxiety and uncertainties brought about by the pandemic. "By following the advice of health authorities you can directly contribute to protecting the lives of people in your community and in doing so to reviving your society's economies in 2021," Kasai said. "I urge you to think about those who may be at high risk of severe COVID. If you catch the virus, you could unknowingly pass it on to your parents or grandparents, your neighbor or friend with an underlying condition," Kasai said. Moreover, he urged the young to "think of health workers who have been working day and night for almost a year. They are exhausted." Kasai also appealed to the governments across the region "to use an additional layer of surveillance that picks up an early sign of infection among those groups that are difficult to catch with the existing system." Kasai said the COVID-19 vaccines "are not a silver bullet that will end the pandemic in the near future." "The development of a safe and effective vaccine is one thing but producing them in adequate quantities and reaching everyone that needs them is another. They will initially only be available in limited quantities and high-risk groups should be prioritized first," he said. "This means that we are tired of this pandemic, we must stick to the actions and behavior which protect not only ourselves but also those around us. Hand washing, mask-wearing, physical distancing and avoiding places that have a high risk of transmission," he added. "For now we must keep making the choices that will reduce transmission of the virus and protect our families and our communities. By doing so we can go into 2021 with hope," Kasai said. Babatunde Olowokure, WHO regional emergency director, echoed Kasai, saying that "COVID-19 vaccine itself is not a silver bullet to end the COVID-19." "There is no room for complacency. So we must continue to remain vigilant, continue to comply with our public health interventions," he said. He further urged governments to "look at strategies" which could help younger population cope with public health interventions and to manage those appropriately. There are now 985,539 confirmed COVID-19 cases in the Western Pacific Region, including 18,641 deaths.  Source: UNB AH
Covid-19 vaccine not a ‘silver bullet’: WHO
US clears Moderna vaccine for Covid-19, 2nd shot in arsenal
The U.S. added a second COVID-19 vaccine to its arsenal Friday, boosting efforts to beat back an outbreak so dire that the nation is regularly recording more than 3,000 deaths a day. Much-needed doses are set to arrive Monday after the Food and Drug Administration authorized an emergency rollout of the vaccine developed by Moderna Inc. and the National Institutes of Health. The move marks the world’s first authorization for Moderna’s shots. The vaccine is very similar to one from Pfizer Inc. and Germany’s BioNTech that’s now being dispensed to millions of health care workers and nursing home residents as the biggest vaccination drive in U.S. history starts to ramp up. The two work “better than we almost dared to hope,” NIH Director Dr. Francis Collins told The Associated Press. “Science is working here, science has done something amazing.” Early results of large, still unfinished studies show both vaccines appear safe and strongly protective although Moderna’s is easier to handle since it doesn’t need to be stored at ultra-frozen temperatures. A second vaccine represents a ray of hope amid despair as the virus continues to spread unabated even before holiday gatherings that are certain to further fuel the outbreak. The scourge has claimed more than 312,000 U.S. lives and killed 1.7 million people worldwide. New cases in the U.S. are running at over 216,000 per day on average. Deaths per day have hit all-time highs, eclipsing 3,600 on Wednesday. California has emerged as one of the most lethal hot spots, with hospitals running out of intensive care beds and ambulances lining up outside emergency rooms in scenes reminiscent of the calamity around New York City last spring. California on Friday reported over 41,000 new cases and 300 more deaths. When New York’s hospitals were in crisis, health care workers from across the country came to help out. This time, “there’s no cavalry coming” because so many hospitals are swamped, said Dr. Marc Futernick, an emergency room physician in Los Angeles. The nation is scrambling to expand vaccinations as rapidly as Moderna and Pfizer can churn out doses. Moderna’s is for people 18 and older, Pfizer’s starts at age 16. It’s just the beginning of “what we hope will be a big push to get this terrible virus behind us, although it will take many more months to get to all Americans,” Collins said. Moderna expects to have between 100 million and 125 million doses available globally in the first three months of 2021, with 85-100 million of those available in the U.S. Even with additional candidates in the pipeline, there won’t be enough for the general population until spring, and shots will be rationed in the meantime. And while health workers are enthusiastically embracing vaccination, authorities worry the public may need more reassurance to ensure more people get in line when it’s their turn. “Frankly if we don’t succeed in getting 80% or so of Americans immunized against COVID-19 by the middle of this 2021 year, we have the risk that this epidemic could go on and on and on,” Collins said. He is especially concerned that accurate information about the shots’ value reaches communities of color, which have been hard-hit by COVID-19 yet also are wary after years of health care disparities and research abuses. To try to help instill confidence, Vice President Mike Pence received the Pfizer-BioNTech shot on live TV Friday, along with Surgeon General Jerome Adams. FDA’s decision could help pave the way for other countries that are considering the Moderna vaccine, the first-ever regulatory clearance for the small Cambridge, Massachusetts, company. European regulators could authorize its use as soon as Jan. 6. Britain, Canada and a few other countries already have cleared the Pfizer-BioNTech shot, with a European Union decision due Monday. “What we want to always remember is one size does not fit all. We want to have options,” said Dr. Paul Duprex of the University of Pittsburgh. Moderna has about 5.9 million doses ready for shipment set to begin over the weekend, according to Operation Warp Speed, the government’s vaccine development program. Injections of health workers and nursing home residents continue next week, before other essential workers and vulnerable groups are allowed to get in line. Both Moderna’s and Pfizer-BioNTech’s shots are so-called mRNA vaccines, made with a groundbreaking new technology. They don’t contain any coronavirus – meaning they cannot cause infection. Instead, they use a piece of genetic code that trains the immune system to recognize the spike protein on the surface of the virus, ready to attack if the real thing comes along. Their development less than a year after the coronavirus first emerged set a speed record, but Collins stressed that shouldn’t worry people. The speed was due to billions in company and government investments paired with years of earlier scientific research, not any cut corners. “The rigor of the analysis of these vaccines is unprecedented,” Collins said. “We’re not done with this but hope is on the way, and the hope comes from this scientific brain trust that has pulled out all the stops.” Experts are hoping the two vaccines together will “break the back of the pandemic” when combined with masks and other precautions, said Dr. Arnold Monto of the University of Michigan, who chaired an advisory committee that publicly debated the shots’ evidence ahead of FDA’s decisions. The FDA’s main messages: --Both the new Moderna vaccine and the Pfizer-BioNTech shot require two doses several weeks apart. The second dose must be from the same company as the first. --In a study of 30,000 volunteers, the Moderna vaccine was more than 94% effective at preventing symptomatic COVID-19 in people 18 and older. It also strongly protected older adults, who are most vulnerable. --The inoculated can’t throw away their masks as it’s not yet clear either vaccine prevents silent, symptomless virus spread. But there was a hint that Moderna’s shot might provide some protection against asymptomatic infection. --The Moderna study uncovered no major safety problems. Like with the Pfizer-BioNTech shot, expect sore arms, fever, fatigue and muscle aches, which are signs the immune system is revving up. --Both vaccines carry “a remote chance” of causing a severe allergic reaction. Moderna’s study turned up none of these, though a handful were reported in Britain as the Pfizer-BioNTech vaccinations got underway and the FDA is looking into five in the U.S., including a severe reaction in Alaska. The vaccines’ ingredients aren’t identical. Still, after any COVID-19 vaccination, people should stick around for 15 minutes – or 30 minutes if they have a history of severe allergies – so if they do have a reaction, it can be treated immediately. --Both vaccines remain experimental, and the government is closely monitoring safety in case rare problems crop up. --Additional studies are needed to tell if the vaccine should be used by pregnant women and children. Women who are pregnant or breastfeeding should discuss whether to get the vaccine with their doctor. Source: AP/UNB AH
US clears Moderna vaccine for Covid-19, 2nd shot in arsenal
French President Macron tests positive for Covid-19
French President Emmanuel Macron has tested positive for COVID-19, the presidential Elysee Palace announced on Thursday. It said the president took a test “as soon as the first symptoms appeared.” The brief statement did not say what symptoms Macron experienced. It said he would isolate himself for seven days. “He will continue to work and take care of his activities at a distance,” it added. It was not immediately clear what contact tracing efforts were in progress. Macron attended a European Union summit at the end of last week, where he notably had a bilateral meeting with German Chancellor Angela Merkel. He met Wednesday with the prime minister of Portugal. There was no immediate comment from Portuguese officials. Macron on Wednesday also held the government’s weekly Cabinet meeting in the presence of Prime Minister Jean Castex and other ministers. Castex’s office said that the prime minister is also self-isolating for seven days. The French presidency confirmed that Macron’s trip to Lebanon scheduled for next week is being canceled. Macron and other government officials repeatedly say that they are sticking to strict sanitary protocols during the pandemic, including not shaking hands, wearing a mask and keeping distance from other people. Macron is following French health authorities’ recommendations that since September have reduced the self-isolation time from 14 days to seven. Authorities said at the time that this is the period when there is the greatest risk of contagion and that reducing it allows better enforcement of the measure. French health authorities argued this week that the 14-day quarantine was not well-respected by many in the country who considered it too long. Source: UNB AH
French President Macron tests positive for Covid-19
Read More
Bangladesh reports 28 Covid-19 deaths, 4,57,459 total recoveries
UK approves AstraZeneca-Oxford virus vaccine as pandemic surges
Bangladesh reports 22 Covid-19 deaths, 4,56,070 total recoveries
Bangladesh reports 27 Covid-19 deaths, 4,53,318 total recoveries